ClinicalTrials.gg
RecruitingNCT04333537Updated Aug 17, 2026

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

A Phase 2/3 interventional study of Chest Radiography and Computed Tomography in Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma and Gingival Squamous Cell Carcinoma, sponsored by NRG Oncology. Recruiting at 107 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by NRG Oncology · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
686
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
24th of 994
686 · median 41
Started
2020
with 69 others
Phase 2/3
12 of 1,099
4 open now
Primary completion
2031-04
later than 324 of 346 live
Registered
675th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 24th largest by planned enrollment of the 994 interventional ones that give a count, is one of 70 that started in 2020, is one of 12 in phase 2/3, reaches primary completion later than 324 of the 346 other live ones, and was the 675th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine if patient-reported neck and shoulder function and related quality of life (QOL) at 6 months after surgery using the Neck Dissection Impairment Index (NDII) is superior with sentinel lymph node (SLN) biopsy compared to elective neck dissection (END) for treatment of early-stage oral cavity squamous cell carcinoma (OCSCC) (cT1-2N0). (Phase II) II. To determine if disease-free survival (DFS) is non-inferior with SLN biopsy compared to END for treatment of early-stage OCSCC (cT1-2N0). (Phase III) III. To determine if patient-reported neck and shoulder function and related QOL at 6 months after surgery using NDII is superior with SLN biopsy compared to END for treatment of early-stage OCSCC (cT1-2N0). (Phase III)

SECONDARY OBJECTIVES:

I. To compare patterns of failure (local-regional relapse and distant metastasis) between surgical arms.

II. To measure and compare overall survival (OS) between surgical arms. III. To measure and compare the toxicity of the two surgical arms.

IV. To measure longitudinal patient-reported neck and shoulder function and related QOL between surgical arms using the following instruments:

IVa. Neck Dissection Impairment Index (NDII); IVb. Abbreviated Disabilities of the Arm, Shoulder and Hand (QuickDASH); IVc. Functional Assessment of Cancer Therapy-Head and Neck (FACT-H\&N). V. To assess the length of hospitalization, post-operative drain placement, and operative morbidity between arms.

VI. To estimate the negative predictive rate of fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/computed tomography (CT) for N0 neck in patients with T1 and T1-2 oral cavity squamous cell cancer (OCSCC) patients in the END arm.

VII. To assess nodal metastases rates between arms. VIII. To assess the pathologic false omission rate (FOR) in the SLN biopsy arm. IX. To determine if patient-reported neck and shoulder function using the NDII and related QOL at 6 months after surgery with SLN biopsy is superior to the END in low-risk patients.

X. To compare the diagnostic performance of planar only versus (vs.) single photon emission computed tomography (SPECT)/CT plus planar for SLN mapping (phase II only).

EXPLORATORY OBJECTIVES:

I. To compare changes in patient-reported outcomes (European Quality of Life Five Dimension Five Level Scale Questionnaire [EQ-5D-5L]) between surgical arms.

II. To collect biospecimens for future translational science studies. III. To assess the DFS between arms in low-risk patients.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy. Patients also undergo FDG PET/CT, CT, and/or chest x-ray at screening and during follow up.

GROUP II: Patients undergo standard END. Patients also undergo FDG PET/CT, CT, and/or chest x-ray at screening and during follow up.

After completion of study treatment, patients are followed up 3 weeks after surgery, every 3 months for year 1, every 4 months for year 2, every 6 months for year 3, then yearly thereafter.

03

Conditions studied

  • Buccal Mucosa Squamous Cell Carcinoma
  • Floor of Mouth Squamous Cell Carcinoma
  • Gingival Squamous Cell Carcinoma
  • Hard Palate Squamous Cell Carcinoma
  • Lip Squamous Cell Carcinoma
  • Lower Alveolar Ridge Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma
  • Retromolar Trigone Squamous Cell Carcinoma
  • Stage I Lip and Oral Cavity Cancer AJCC v8
  • Stage II Lip and Oral Cavity Cancer AJCC v8
  • Tongue Squamous Cell Carcinoma
  • Upper Alveolar Ridge Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PRIOR TO STEP 1 REGISTRATION INCLUSION:
  • Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (SCC) of the oral cavity, including the oral (mobile) tongue, floor of mouth (FOM), mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, retromolar gingiva (retromolar trigone; RMT), or hard palate prior to registration
  • Appropriate stage for study entry (T1-2N0M0; American Joint Committee on Cancer [AJCC] 8th edition [ed.]) based on the following diagnostic workup:

    • History/physical examination within 42 days prior to registration
    • Imaging of head and neck within 42 days prior to registration

      • PET/CT scan or contrast neck CT scan, or gadolinium-enhanced neck magnetic resonance imaging (MRI) or lateral and central neck ultrasound; diagnostic quality CT is preferred and highly recommended as part of the PET/CT when possible
    • Imaging of chest within 42 days prior to registration

      • Chest x-ray, CT chest scan (with or without contrast), or PET/CT (with or without contrast)
  • Surgical assessment within 42 days prior to registration. Patient must be a candidate for surgical intervention with sentinel lymph node (SLN) and potential completion neck dissection (CND) or elective neck dissection (END)

    • Surgical resection of the primary tumor will occur through a transoral approach with anticipation of resection free margins
  • Age >= 18
  • Zubrod performance status 0-2 within 42 days prior to registration
  • For women of , negative serum or urine pregnancy test within 42 days prior to registration
  • The patient or a legally authorized representative must provide study-specific prior to study entry
  • Only patients who are able to read and understand English or French are eligible to participate as the mandatory patient reported NDII tool is only available in these languages
  • PRIOR TO STEP 2 RANDOMIZATION:
  • FDG PET/CT required prior to step 2. Note: FDG PET/CT done prior to step 1 can be submitted for central review

    • PET/CT node negative patients, determined by central read, will proceed to randomization. PET/CT node positive patients will go off study, but will be entered in a registry and data will be collected to record the pathological outcome of neck nodes for diagnostic imaging assessment and future clinical trial development

      • NOTE: All FDG PET/CT scans must be performed on an American College of Radiology (ACR) accredited scanner (or similar accrediting organization)
  • The patient must complete NDII prior to step 2 registration

Exclusion criteria

Exclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION EXCLUSION:
  • Definitive clinical or radiologic evidence of regional (cervical) and/or distant disease
  • Prior non-head and neck invasive (except non-melanomatous skin cancer, including effectively treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix) unless disease free for ≥ 2 years
  • Diagnosis of head and neck SCC in the oropharynx, nasopharynx, hypopharynx, and larynx
  • Unable or unwilling to complete NDII (baseline only)
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for different cancer(s) is allowable
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • Severe, active co-morbidity that would preclude an elective or completion neck dissection
  • Pregnancy and breast-feeding mothers
  • Incomplete resection of oral cavity lesion with a positive margin; however, an excisional is permitted
  • Prior surgery involving the lateral neck, including neck dissection or gross injury to the neck that would preclude surgical dissection for this trial. Prior thyroid and central neck surgery is permissible; biopsy is permitted. Note: Borderline suspicious nodes that are >= 1 cm with radiographic finding suggestive of NOT malignant should be biopsied using ultrasound (U/S)-guided fine-needle aspiration (FNA) biopsy
  • Underlying or documented history of hematologic malignancy (e.g., chronic lymphocytic leukemia [CLL]) or other active disease capable of causing lymphadenopathy (e.g., sarcoidosis or untreated mycobacterial infection)
  • Actively receiving systemic cytotoxic chemotherapy, , anti-monocyte or immunomodulatory therapy
  • Currently participating in another therapeutic trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
686 participants (estimated)

Study arms

  • Experimental
    Group I (SLN biopsy)

    Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy. Patients also undergo FDG PET/CT, CT, and/or chest x-ray at screening and during follow up.

    Procedure: Chest Radiography · Procedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Drug: Imaging Agent · Procedure: Planar Imaging · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Procedure: Sentinel Lymph Node Biopsy · Procedure: Single Photon Emission Computed Tomography

  • Active comparator
    Group II (END)

    Patients undergo standard END. Patients also undergo FDG PET/CT, CT, and/or chest x-ray at screening and during follow up.

    Procedure: Chest Radiography · Other: Fludeoxyglucose F-18 · Procedure: Neck Dissection · Procedure: Positron Emission Tomography · Other: Questionnaire Administration

Interventions

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: Chest X-ray

  • ProcedureComputed Tomography

    Undergo SPECT/CT scan and FDG PET/CT or CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • OtherFludeoxyglucose F-18

    Undergo FDG PET/CT

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • DrugImaging Agent

    Receive imaging agent via injection

    Also known as: Image Enhancement Agent

  • ProcedureNeck Dissection

    Undergo standard elective neck dissection

  • ProcedurePlanar Imaging

    Undergo planar imaging

  • ProcedurePositron Emission Tomography

    Undergo FDG PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureSentinel Lymph Node Biopsy

    Undergo SLN biopsy

    Also known as: Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB

  • ProcedureSingle Photon Emission Computed Tomography

    Undergo SPECT/CT scan

    Also known as: Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon

06

What researchers measure

Primary outcomes

  1. Patient-reported neck and shoulder function (Phase II/III)

    Will be evaluated and compared using the Neck Dissection Impairment Index (NDII), a 10-item tool between the two treatment arms. It is assumed that a 7.5-point between arm difference in the 6-month post-surgery NDII scores is clinically meaningful.

    Time frame: Before surgery (Baseline), 3 weeks after surgery, 3, 6, 12 months after surgery

  2. Patient reported quality of life (QOL) (Phase II)

    Will be measured using 3 questionnaires over 12-15 minutes.

    Time frame: Before surgery (Baseline), 3 weeks after surgery, 3, 6, 12 months after surgery

  3. Disease-free survival (DFS) (phase III)

    Measured using Cox proportional hazards model and the Kaplan-Meier method. Failure includes local/regional recurrence, distant metastasis, or death due to any cause.

    Time frame: From randomization to local/regional recurrence, distant metastasis, or death due to any cause, whichever comes first, assessed up to 11 years

Secondary outcomes

  1. Overall survival rate

    Will be estimated using the Kaplan-Meier method and between-arm differences compared using the log-rank test.

    Time frame: From randomization to death due to any cause, assessed up to 11 years

  2. Loco-regional failure

    The cumulative incidence estimator will be used to estimate time to event distributions with between arm differences using cause-specific log-rank test.

    Time frame: From the time of randomization to the date of failure, date of precluding event, or last known follow-up date, assessed up to 11 years

  3. Distant metastasis

    The cumulative incidence estimator will be used to estimate event distributions with between arm differences tested using cause-specific log-rank test.

    Time frame: From the time of randomization to the date of distant metastasis, date of precluding event, or last known follow-up date, assessed up to 11 years

  4. Toxicity

    Measured by the Common Terminology Criteria for Adverse Events version 5.0. The proportion of patients with at least 1 grade 3 or higher adverse event will be compared between treatment arms.

    Time frame: Time of primary endpoint analysis

  5. Patient-reported shoulder-related QOL, function impairment and disability

    Patient reported using Abbreviated Disabilities of the Arm, Shoulder, and Hand (QuickDASH) with scores of 0-100. A higher score indicates greater disability.

    Time frame: Baseline, 3 weeks, 3, 6, 12 months post-surgery

  6. General quality of life

    Will be measured using the Functional Assessment of Cancer Therapy-Head and Neck to measure Functional Assessment of Cancer Therapy-Head and Neck-Trial Outcome Index scores on a scale from 0-96. A higher score indicates better quality of life.

    Time frame: Baseline, 3 weeks, 3, 6, 12 months post-surgery

  7. Nodal metastasis detection rate

    Defined as the proportion of patients with pathologic positive nodes using the pathology results.

    Time frame: At time of surgery

  8. Pathologic false omission rate

    Measured within the sentinel lymph node biopsy (SLN) arm only. Defined as the proportion of patients with false negative results among negative SLN patients.

    Time frame: At time of surgery

  9. Length of hospital stay

    Length of hospital stay due to surgical procedure will be compared between arms using the Mann-Whitney test.

    Time frame: Prior to surgery, at time of discharge from surgery

  10. Post-surgery patient-reported outcome

    Measured by NDII in low-risk oral cavity squamous cell carcinoma patients using analysis of covariance comparison model.

    Time frame: At 6 months post-surgery

  11. Diagnostic performance (Phase II only)

    Descriptive statistics (minimum, maximum, mean, standard deviation, and coefficient of variation) of the number of detected SLNs will be calculated by modality and neck sublevel. The difference of the number of SLNs between single photon emission computed tomography/computed tomography plus planar and planar only will be computed and summarized by neck sublevel, reader, and overall. Pairwise absolute differences of the number of detected SLNs among readers will be computed and summarized by modality and neck sublevel.

    Time frame: Up to 11 years

Other outcomes

  1. Quality of life

    Measured by European Quality of Life Five Dimension Five Level Scale Questionnaire.

    Time frame: Baseline, 3 weeks, and 3, 6, 12 months post-surgery

  2. DFS for low-risk patients

    Exploratory analyses will be done using the Kaplan-Meier method to estimate the DFS distribution in both arms. Cox proportional hazards models with the treatment arm only and with treatment arms and relevant patient and tumor characteristics will be fitted. 95% confidence intervals (CIs) for the treatment effect from both models will be also reported.

    Time frame: From randomization to local/regional recurrence, distant metastasis, or death due to any cause, whichever comes first, assessed up to 11 years

07

Study locations

88 of 107 sites recruiting

Showing the first 100 of 107 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Apr 2031, 127 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2020
First posted
Apr 3, 2020
StartActual
Sep 23, 2020
Primary completionEst.
Apr 27, 2031
CompletionEst.
Apr 27, 2036
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04333537
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Sep 23, 2020
Primary completion
Apr 27, 2031 (estimated)
Completion
Apr 27, 2036 (estimated)
Last update
Aug 17, 2026

Study contacts

Stephen Y Lai
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion